🇺🇸 FDA
Patent

US 12083227

Solid pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis

granted A61KA61K31/513A61K9/2009

Quick answer

US patent 12083227 (Solid pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis) held by Neurocrine Biosciences, Inc. expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Neurocrine Biosciences, Inc.
Grant date
Tue Sep 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
46
CPC classes
A61K, A61K31/513, A61K9/2009, A61K9/2013, A61K9/2027